Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPRA424: [⁶⁴Cu]Cu-RAX301 PET/CT in Prostate Cancer
NCT07765940Phase 2Not yet recruiting
- Sponsor
- RadAlliance Therapeutics
- Start
- Sep 2026
- Primary completion
- Jun 2027
01
Overview
A Phase 2 trial of Cu-RAX301 in prostate cancer (PCa), sponsored by RadAlliance Therapeutics. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Cu-RAX301
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07765940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765940.